201 Industrial Rd
8 articles with Nautilus Biotechnology
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the proteome, announced the appointment of Emma Lundberg, Ph.D. to its Scientific Advisory Board.
Nautilus Biotechnology Debuts as Publicly Traded Company, Seeks to Deliver on the Untapped Potential of the Human Proteome
Nautilus Biotechnology, Inc. announced the completion of its business combination with Arya Sciences Acquisition Corp III, a special purpose acquisition company sponsored by Perceptive Advisors.
Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the company will be participating in the upcoming Goldman Sachs 42nd Annual Global Healthcare Conference. Nautilus’ management is scheduled to present on Thursday, June 10th at 3:00 p.m. Eastern Time/12:00 p.m. Pacific Time.
Nautilus Biotechnology, Inc., a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, today announced the appointment of Matt Murphy, Esq., as General Counsel.
2/10/2021The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
According to NASDAQ, SPACs – Special Purpose Acquisition Companies – now make up more than a third of all IPOs.
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III
Nautilus Biotechnology has entered into a definitive merger agreement with Arya Sciences Acquisition Corp III (Nasdaq: ARYA). Upon closing, the combined company is expected to be listed on Nasdaq under the ticker symbol “NAUT” Nautilus Biotechnology is expected to receive $350 million in proceeds through the business combination, including a $200 million fully committed PIPE led by Perceptive Advisors and other top-tier healthcare investors
Proven leaders in product, finance, and marketing to accelerate the development of Nautilus’ next-generation, single-molecule proteomics analysis platform